| Symbol | IUGNF |
|---|---|
| Name | IMUGENE, LTD. |
| Sector | UNDEFINED |
| Region | Oceania |
| Industry | - |
| Address | 2000 Australia NSW 37 Bligh Street, Suite 1006, Level 10 |
| Telephone | +61.3.98245254 |
| Fax | — |
| — | |
| Website | http://www.imugene.com |
| Incorporation | AU |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| CIK | — |
| Description | Imugene is a clinical stage immuno-oncology company developing a range of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumors. Additional info from OTC: |
No news found.